Conference abstract · 18 Jun 2020
Conference abstractPublished 8 Oct 2015
cGMP considerations for parenteral formulations
Indore Institute of Pharmacy, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmaceutical formulations have evolved from simple products to sophisticated devices and delivery systems over the last decade. Continuous efforts to make cost effective and safe medicines has always been the forefront of the Indian pharmaceutical industry. Technological advances in the areas of design, manufacturing technology, quality testing, and regulatory compliance of Pharmaceuticals has become challenging. Current Good Manufacturing Practices (cGMP) assist the industry in developing sustainable strategies for quality processes. It has been interestingly observed that the number of batches failing in quality as per regulatory standards has not decreased over the years. Looking at the USFDA recalls it is clear that cGMP violations accounts for the majority of failures. This has led to a lot of introspection. Parenteral products are more vulnerable since they require stringent manufacturing controls to prevent product failure. Problems of particulate matter and sterility account for major reasons. An in-depth study of product recalls was carried out and the causes of failure were classified. Data obtained was analyzed and grouped to assess the findings. Correlation was established as to which cGMP violations were responsible for product failure. Class I, II and III recalls were also correlated with the reasons of product failure. The findings have been tabulated and presented.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2019
Pharmacology 2019 - FDA cGMP requirements for combination products â?? considerations for drug manufacturers - Viky Verna - University of Florida
Conference abstract · 12 Nov 2013
Moving beyond Part 11; Quality assurance considerations for translating cGMP compliance into electronic batch record initiatives
Editorial · 2017
Basic Considerations for Container Closure Selection of Parenteral Drug Products
Perspective · 20 May 2022
Parenteral formulations that use cyclodextrin as a delivery mechanism: a review and update
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Praful D Bharadia”

